{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:18:49Z","timestamp":1794100729985,"version":"4.8.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades of Spain","award":["BFU2017-82805-C2-1-P"],"award-info":[{"award-number":["BFU2017-82805-C2-1-P"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.antiviral.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T11:38:51Z","timestamp":1553341131000},"page":"19-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"special_numbering":"C","title":["HIV \u201cshock and kill\u201d therapy: In need of revision"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6529-3161","authenticated-orcid":false,"given":"Erik","family":"Abner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.03.008_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005677","article-title":"Human galectin-9 is a potent mediator of HIV transcription and reactivation","volume":"12","author":"Abdel-Mohsen","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02056-17","article-title":"A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other \u201cshock\u201d drugs","volume":"92","author":"Abner","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib3","doi-asserted-by":"crossref","first-page":"9592","DOI":"10.1093\/nar\/gkr698","article-title":"Signal-induced Brd4 release from chromatin is essential for its role transition from chromatin targeting to transcriptional regulation","volume":"39","author":"Ai","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib4","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1038\/s41598-017-07814-4","article-title":"Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation","volume":"7","author":"Albert","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12977-017-0335-8","article-title":"Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells","volume":"14","author":"Alvarez-Carbonell","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib6","doi-asserted-by":"crossref","first-page":"E1528","DOI":"10.1073\/pnas.1320178111","article-title":"Heat shock protein 90 controls HIV-1 reactivation from latency","volume":"111","author":"Anderson","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.03.008_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/jiu155","article-title":"HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat","volume":"210","author":"Archin","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib8","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1172\/JCI92684","article-title":"Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","volume":"127","author":"Archin","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.03.008_bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.008_bib10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrmicro3352","article-title":"Eradicating HIV-1 infection: seeking to clear a persistent pathogen","volume":"12","author":"Archin","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1089\/088922202320935438","article-title":"Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy","volume":"18","author":"Asj\u00f6","year":"2002","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2019.03.008_bib12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41556-018-0233-x","article-title":"Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours","volume":"20","author":"Avgustinova","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.09.004","article-title":"The thioacetate-\u03c9(\u03b3-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent","volume":"123","author":"Badia","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","article-title":"Small-molecule SMAC mimetics as new cancer therapeutics","volume":"144","author":"Bai","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2019.03.008_bib15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1189\/jlb.0312165","article-title":"BET bromodomain inhibition as a novel strategy for reactivation of HIV-1","volume":"92","author":"Banerjee","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib16","series-title":"Farnesyl-Transferase inhibitors: Identification and validation of a class which reactivates HIV latent expression and is synergistic with other mechanisms in vitro","author":"Barnard","year":"2013"},{"key":"10.1016\/j.antiviral.2019.03.008_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1255512","article-title":"Immunologic strategies for HIV-1 remission and eradication","volume":"345","author":"Barouch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.03.008_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102684","article-title":"Selective HDAC inhibition for the disruption of latent HIV-1 infection","volume":"9","author":"Barton","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34655","article-title":"Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells","volume":"7","author":"Battivelli","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2019.03.008_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bcp.2008.11.025","article-title":"SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro","volume":"77","author":"Bedoya","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bcp.2015.02.009","article-title":"Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription","volume":"94","author":"Bermejo","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib22","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.febslet.2011.10.018","article-title":"The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response","volume":"585","author":"Bernhard","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.antiviral.2019.03.008_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.chom.2016.11.001","article-title":"The mTOR complex controls HIV latency","volume":"20","author":"Besnard","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.008_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000554","article-title":"CpG methylation controls reactivation of HIV from latency","volume":"5","author":"Blazkova","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0166-3542(03)00034-2","article-title":"Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate","volume":"59","author":"Bocklandt","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4161\/cc.23309","article-title":"BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism","volume":"12","author":"Boehm","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.antiviral.2019.03.008_bib27","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/v5061571","article-title":"Bromodomain proteins in HIV infection","volume":"5","author":"Boehm","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.03.008_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.chom.2017.04.011","article-title":"SMYD2-Mediated histone methylation contributes to HIV-1 latency","volume":"21","author":"Boehm","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.008_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0006-291X(87)80217-6","article-title":"Sodium butyrate activates human immunodeficiency virus long terminal repeat--directed expression","volume":"148","author":"Bohan","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2019.03.008_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature20583","article-title":"Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys","volume":"540","author":"Borducchi","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.008_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2019.03.008_bib32","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.celrep.2017.01.022","article-title":"Benzotriazoles reactivate latent HIV-1 through inactivation of STAT5 SUMOylation","volume":"18","author":"Bosque","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15252\/emmm.201505557","article-title":"Sequential treatment with 5-aza-2\u2019-deoxycytidine and deacetylase inhibitors reactivates HIV-1","volume":"8","author":"Bouchat","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2055-6640(20)30818-9","article-title":"O2: identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1","volume":"3","author":"Bouchat","year":"2017","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.antiviral.2019.03.008_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.celrep.2018.09.020","article-title":"Single-cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency","volume":"25","author":"Bradley","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.antiviral.2019.03.008_bib37","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nm.3489","article-title":"Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo","volume":"20","author":"Bullen","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.virol.2013.07.037","article-title":"Dual-color HIV reporters trace a population of latently infected cells and enable their purification","volume":"446","author":"Calvanese","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168027","article-title":"Euphorbia kansui reactivates latent HIV","volume":"11","author":"Cary","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/biom7010003","article-title":"DNA methylation targeting: the DNMT\/HMT crosstalk challenge","volume":"7","author":"Castillo-Aguilera","year":"2017","journal-title":"Biomolecules"},{"key":"10.1016\/j.antiviral.2019.03.008_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nsmb.3328","article-title":"Position effects influence HIV latency reversal","volume":"24","author":"Chen","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib43","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1002\/cpmb.56","article-title":"Using barcoded HIV Ensembles (B-HIVE) for single provirus transcriptomics","volume":"122","author":"Chen","year":"2018","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib44","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/JVI.05065-11","article-title":"Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes","volume":"86","author":"Chiang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/QAD.0b013e328333bfa1","article-title":"Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1","volume":"24","author":"Choi","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1084\/jem.188.1.83","article-title":"Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines","volume":"188","author":"Chun","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib47","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrmicro2223","article-title":"Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs","volume":"7","author":"Coiras","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib48","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1074\/jbc.M807898200","article-title":"Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells","volume":"284","author":"Contreras","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib49","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"Cummins","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00012-17","article-title":"Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition","volume":"91","author":"Cummins","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib51","doi-asserted-by":"crossref","first-page":"14592","DOI":"10.1073\/pnas.1200037109","article-title":"Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF\u03b2 interaction","volume":"109","author":"Cunningham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2019.03.008_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005063","article-title":"An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression","volume":"11","author":"Darcis","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib54","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/COH.0000000000000288","article-title":"Preclinical shock strategies to reactivate latent HIV-1: an update","volume":"11","author":"Darcis","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib55","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2019.03.008_bib56","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fimmu.2018.01514","article-title":"In vitro exposure to prostratin but not bryostatin-1 improves natural killer cell functions including killing of CD4+ T cells harboring reactivated human immunodeficiency virus","volume":"9","author":"Desimio","year":"2018","journal-title":"Front. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2019.03.008_bib57","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"28","author":"Dickinson","year":"2010","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.antiviral.2019.03.008_bib58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.chom.2012.12.005","article-title":"Tousled-like kinases modulate reactivation of gammaherpesviruses from latency","volume":"13","author":"Dillon","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.008_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084964","article-title":"Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110\u03b1 that reactivates latent HIV-1","volume":"9","author":"Doyon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib60","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e3283570620","article-title":"Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog","volume":"27","author":"Doyon","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1086\/338123","article-title":"Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection","volume":"185","author":"Dybul","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"Suppl 5","key":"10.1016\/j.antiviral.2019.03.008_bib230","first-page":"1","article-title":"Abstracts of the 8th HIV persistence during therapy workshop","volume":"3","author":"Elbezanti","year":"2017","journal-title":"J. Virus Eradic."},{"key":"10.1016\/j.antiviral.2019.03.008_bib62","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2019.03.008_bib63","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib64","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/8394","article-title":"Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy","volume":"5","author":"Finzi","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib65","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","article-title":"Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.antiviral.2019.03.008_bib67","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.140.4.1117","article-title":"Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate","volume":"140","author":"Folks","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib68","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1128\/JVI.00836-11","article-title":"Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of zeste 2\u25bf","volume":"85","author":"Friedman","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib70","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fmicb.2017.00689","article-title":"The role of HCMV and HIV-1 MicroRNAs: processing, and mechanisms of action during viral infection","volume":"8","author":"Fruci","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib71","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.18632\/oncotarget.3551","article-title":"Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.antiviral.2019.03.008_bib72","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/JVI.05972-11","article-title":"Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1","volume":"86","author":"Gallastegui","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib73","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/JVI.01920-10","article-title":"Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency","volume":"85","author":"Gallastegui","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.aaf8094","article-title":"Shock and kill with caution","volume":"354","author":"Gallo","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.03.008_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib76","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib77","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1038\/s41598-018-21942-5","article-title":"BI-2536 and BI-6727, dual Polo-like kinase\/bromodomain inhibitors, effectively reactivate latent HIV-1","volume":"8","author":"Gohda","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib78","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0000000000001948","article-title":"HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients","volume":"32","author":"Golob","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2055-6640(20)30522-7","article-title":"Abstracts of the 8th HIV persistence during therapy workshop","volume":"3","author":"Gramatica","year":"2017","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.antiviral.2019.03.008_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006004","article-title":"Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents","volume":"14","author":"Gupta","year":"2018","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib81","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Guti\u00e9rrez","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib82","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1574-6976.2012.00335.x","article-title":"HIV latency: experimental systems and molecular models","volume":"36","author":"Hakre","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.03.008_bib83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1570162043484915","article-title":"Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it","volume":"2","author":"Hamer","year":"2004","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib84","doi-asserted-by":"crossref","first-page":"10227","DOI":"10.1128\/JVI.77.19.10227-10236.2003","article-title":"Rational design of drugs that induce human immunodeficiency virus replication","volume":"77","author":"Hamer","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrm.2016.159","article-title":"Histone chaperone networks shaping chromatin function","volume":"18","author":"Hammond","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib86","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0042-6822(86)90451-4","article-title":"Tumor promoter, TPA, enhances replication of HTLV-III\/LAV","volume":"154","author":"Harada","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib87","doi-asserted-by":"crossref","first-page":"160","DOI":"10.15252\/emmm.201708193","article-title":"Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency","volume":"10","author":"Hashemi","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058586","article-title":"Identification of human microRNA-like sequences embedded within the protein-encoding genes of the human immunodeficiency virus","volume":"8","author":"Holland","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib89","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01844-17","article-title":"Long noncoding RNA uc002yug.2 activates HIV-1 latency through regulation of mRNA levels of various RUNX1 isoforms and increased tat expression","volume":"92","author":"Huan","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib90","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib91","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3389\/fmicb.2017.01035","article-title":"A novel bromodomain inhibitor reverses HIV-1 latency through specific binding with BRD4 to promote tat and P-TEFb association","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib92","article-title":"Picomolar dichotomous activity of gnidimacrin against HIV-1","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib93","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/acsmedchemlett.8b00012","article-title":"Elimination of HIV-1 latently infected cells by gnidimacrin and a selective HDAC inhibitor","volume":"9","author":"Huang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2019.03.008_bib94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ebiom.2016.04.032","article-title":"Small molecule inhibitor of CBF\u03b2-RUNX binding for RUNX transcription factor driven cancers","volume":"8","author":"Illendula","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2019.03.008_bib95","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1074\/jbc.M110.103531","article-title":"Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294","volume":"285","author":"Imai","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib96","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/QAD.0000000000000289","article-title":"Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C\u03b4-NF-\u03baB signaling","volume":"28","author":"Jiang","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005066","article-title":"Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation","volume":"11","author":"Jiang","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib98","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1172\/JCI98071","article-title":"HIV latency is reversed by ACSS2-driven histone crotonylation","volume":"128","author":"Jiang","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.03.008_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005545","article-title":"A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes","volume":"12","author":"Jones","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004287","article-title":"Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes","volume":"10","author":"Jones","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib101","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.1074\/jbc.M116.717538","article-title":"Inhibition of Heat shock protein 90 prevents HIV rebound","volume":"291","author":"Joshi","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.antiviral.2019.03.008_bib231","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101703","article-title":"Triterpenoids from Ocimum labiatum activates latent HIV-1 expression in vitro: potential for use in adjuvant therapy","volume":"22","author":"Kapewangolo","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2019.03.008_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000495","article-title":"Epigenetic regulation of HIV-1 latency by cytosine methylation","volume":"5","author":"Kauder","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib103","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cBlock-and-Lock\u201d strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-018-0421-6","article-title":"HIV latency reversing agents act through Tat post translational modifications","volume":"15","author":"Khoury","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib105","doi-asserted-by":"crossref","first-page":"28896","DOI":"10.1038\/srep28896","article-title":"Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib106","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201ckill\u201d into \u201cshock and kill\u201d: strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.008_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003997","article-title":"Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA","volume":"10","author":"Klase","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib109","first-page":"8239428","article-title":"A critical review of the evidence concerning the HIV latency reversing effect of disulfiram, the possible explanations for its inability to reduce the size of the latent reservoir in vivo, and the caveats associated with its use in practice","volume":"2017","author":"Knights","year":"2017","journal-title":"AIDS Res. Treat."},{"key":"10.1016\/j.antiviral.2019.03.008_bib110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1099\/jgv.0.000716","article-title":"Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells","volume":"98","author":"Kobayashi","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib111","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood.V98.10.3006","article-title":"Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART","volume":"98","author":"Kulkosky","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2019.03.008_bib112","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1086\/344357","article-title":"Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy","volume":"186","author":"Kulkosky","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib113","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.1021\/acs.jmedchem.5b01233","article-title":"Gnidimacrin, a potent anti-HIV diterpene, can eliminate latent HIV-1 ex vivo by activation of protein kinase C \u03b2","volume":"58","author":"Lai","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib114","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","article-title":"Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations","volume":"125","author":"Laird","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.03.008_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat4985","article-title":"Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors","volume":"4","author":"Lee","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.antiviral.2019.03.008_bib116","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","article-title":"Depletion of latent HIV-1 infection in vivo: a proof-of-concept study","volume":"366","author":"Lehrman","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.antiviral.2019.03.008_bib232","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1021\/ol503349y","article-title":"Abyssomicin 2 reactivates latent HIV-1 by a PKC- and HDAC-independent mechanism","volume":"17","author":"Le\u00f3n","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.antiviral.2019.03.008_bib117","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2019.03.008_bib118","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cid\/cis383","article-title":"Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I\/IIa randomized, placebo-controlled, multicenter study","volume":"55","author":"L\u00e9vy","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007012","article-title":"The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency","volume":"14","author":"Li","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.09.015","article-title":"Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor","volume":"227","author":"Lim","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib122","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bcp.2018.08.042","article-title":"PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1","volume":"156","author":"Lin","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib123","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/157016211796320333","article-title":"HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells","volume":"9","author":"Lin","year":"2011","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib124","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ejmech.2018.07.020","article-title":"Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui","volume":"156","author":"Liu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib126","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41598-017-02634-y","article-title":"The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1","volume":"7","author":"L\u00f3pez-Huertas","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib127","doi-asserted-by":"crossref","first-page":"24100","DOI":"10.1038\/srep24100","article-title":"The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb","volume":"6","author":"Lu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib128","doi-asserted-by":"crossref","first-page":"16646","DOI":"10.1038\/s41598-017-16816-1","article-title":"BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency","volume":"7","author":"Lu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrmicro.2016.162","article-title":"Nuclear landscape of HIV-1 infection and integration","volume":"15","author":"Lusic","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib130","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122673","article-title":"Dual TLR2 and TLR7 agonists as HIV latency-reversing agents","volume":"3","author":"Macedo","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.antiviral.2019.03.008_bib131","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01931-17","article-title":"Maraviroc is associated with latent HIV-1 reactivation through NF-\u03baB activation in resting CD4+ T cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy","author":"Madrid-Elena","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.08.004","article-title":"Small molecule targeting of specific BAF (mSWI\/SNF) complexes for HIV latency reversal","author":"Marian","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib133","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.virol.2018.05.006","article-title":"Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents","volume":"520","author":"Marsden","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3181d3dca3","article-title":"The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro","volume":"54","author":"Matalon","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2019.03.008_bib136","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2119\/molmed.2011.00076","article-title":"Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir","volume":"17","author":"Matalon","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-virology-101416-041646","article-title":"The molecular basis for human immunodeficiency virus latency","volume":"4","author":"Mbonye","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib138","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/np400889x","article-title":"Study of marine natural products including resorcyclic acid lactones from humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells","volume":"77","author":"Mejia","year":"2014","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.antiviral.2019.03.008_bib139","series-title":"Defining the Molecular Mechanisms of HIV-1 Tat Secretion: PtdIns(4,5)P2 at the Epicenter","author":"Mele","year":"2018"},{"key":"10.1016\/j.antiviral.2019.03.008_bib140","doi-asserted-by":"crossref","first-page":"21083","DOI":"10.1074\/jbc.M110.195537","article-title":"High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor","volume":"286","author":"Micheva-Viteva","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib141","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.bmcl.2014.11.067","article-title":"Development of novel Asf1-H3\/H4 inhibitors","volume":"25","author":"Miknis","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2019.03.008_bib142","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1742-4690-10-120","article-title":"Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication","volume":"10","author":"Miller","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib143","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41467-018-04941-y","article-title":"Molecular basis of tousled-like kinase 2 activation","volume":"9","author":"Mortuza","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.03.008_bib144","series-title":"Viral Control Induced by Hivconsv Vaccines & Romidepsin in Early Treated Individuals | CROI Conference","author":"Mothe","year":"2017"},{"key":"10.1016\/j.antiviral.2019.03.008_bib145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2012.05.016","article-title":"An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription","volume":"12","author":"Mousseau","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.008_bib146","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00465-15","article-title":"The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency","volume":"6","author":"Mousseau","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2019.03.008_bib147","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/14787210.2016.1122525","article-title":"Didehydro-Cortistatin A: a new player in HIV-therapy?","volume":"14","author":"Mousseau","year":"2016","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2019.03.008_bib148","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejmech.2016.02.043","article-title":"Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation","volume":"114","author":"Myrianthopoulos","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib149","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4049\/jimmunol.142.2.531","article-title":"Induction of IL-6 (B cell stimulatory factor-2\/IFN-beta 2) production by HIV","volume":"142","author":"Nakajima","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib150","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00037-18","article-title":"HIV protease-generated Casp8p41, when bound and inactivated by Bcl2, is degraded by the proteasome","volume":"92","author":"Natesampillai","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib151","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00133-17","article-title":"Multiple histone lysine methyltransferases are required for the establishment and maintenance of HIV-1 latency","volume":"8","author":"Nguyen","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2019.03.008_bib152","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/sj.cdd.4401094","article-title":"HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation","volume":"9","author":"Nie","year":"2002","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.antiviral.2019.03.008_bib153","first-page":"1","article-title":"Abstracts of the 8th HIV persistence during therapy workshop","volume":"3","author":"Nikolai","year":"2017","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.antiviral.2019.03.008_bib154","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1158\/0008-5472.CAN-15-2721","article-title":"Cancer differentiating agent Hexamethylene bisacetamide inhibits BET bromodomain proteins","volume":"76","author":"Nilsson","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1742-4690-10-119","article-title":"Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1\/2 stimulation","volume":"10","author":"Novis","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib156","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1128\/JVI.00222-16","article-title":"A novel toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-Infected autologous CD4+ T cells","volume":"90","author":"Offersen","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib157","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1074\/jbc.M608150200","article-title":"Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1\/SP3 transcription factors","volume":"282","author":"Oguariri","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib158","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1074\/jbc.275.1.279","article-title":"Requirement for a kinase-specific chaperone pathway in the production of a Cdk 9\/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription","volume":"275","author":"O'Keeffe","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib159","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.chom.2015.08.009","article-title":"BIRC2\/cIAP1 is a negative regulator of HIV-1 transcription and can Be targeted by smac mimetics to promote reversal of viral latency","volume":"18","author":"Pache","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2019.03.008_bib160","doi-asserted-by":"crossref","first-page":"26177","DOI":"10.1074\/jbc.M116.743906","article-title":"Heat shock protein 90 facilitates latent HIV reactivation through maintaining the function of positive transcriptional elongation factor b (p-TEFb) under proteasome inhibition","volume":"291","author":"Pan","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib161","article-title":"Heat shock factor 1 mediates latent HIV reactivation","volume":"6","author":"Pan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib162","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2014.05.033","article-title":"Reactivation of latent HIV-1 by new semi-synthetic ingenol esters","volume":"462\u2013463","author":"Pandel\u00f3 Jos\u00e9","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib163","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1473-3099(13)70343-8","article-title":"Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial","volume":"14","author":"Pollard","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib164","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","article-title":"Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy","volume":"13","author":"Prins","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib165","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2019.03.008_bib166","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","volume":"22","author":"Rathore","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.antiviral.2019.03.008_bib167","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006678","article-title":"Single-cell analysis identifies cellular markers of the HIV permissive cell","volume":"13","author":"Rato","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib168","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1038\/s41467-018-06843-5","article-title":"A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation","volume":"9","author":"Reeves","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2019.03.008_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/v10070348","article-title":"Identification of novel HIV-1 latency-reversing agents from a library of marine natural products","volume":"10","author":"Richard","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.03.008_bib170","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02084-16","article-title":"Promising role of toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV","volume":"91","author":"Rochat","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080938","article-title":"Mycobacterial phosphatidylinositol mannoside 6 (PIM6) up-regulates TCR-triggered HIV-1 replication in CD4+ T cells","volume":"8","author":"Rodriguez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib172","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/JVI.02174-14","article-title":"Autophagy restricts HIV-1 infection by selectively degrading Tat in CD4+ T lymphocytes","volume":"89","author":"Sagnier","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib173","first-page":"312447","article-title":"The SMAC mimetic AZD5582 is a potent HIV latency reversing agent","author":"Sampey","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2019.03.008_bib174","doi-asserted-by":"crossref","first-page":"21897","DOI":"10.1074\/jbc.M311609200","article-title":"CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells","volume":"279","author":"Scheller","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib175","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.176.5.2888","article-title":"TLR7\/8 triggering exerts opposing effects in acute versus latent HIV infection","volume":"176","author":"Schlaepfer","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib176","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.1003174","article-title":"TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-\u03b1","volume":"186","author":"Schlaepfer","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib177","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/nar\/gkr719","article-title":"Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs","volume":"40","author":"Schopman","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib178","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bcp.2017.07.001","article-title":"On the way to find a cure: purging latent HIV-1 reservoirs","volume":"146","author":"Schwartz","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib179","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12860-017-0130-3","article-title":"Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells","volume":"18","author":"Seo","year":"2017","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib180","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5483\/BMBRep.2015.48.12.063","article-title":"Identification of small molecules that inhibit the histone chaperone Asf1 and its chromatin function","volume":"48","author":"Seol","year":"2015","journal-title":"BMB Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib181","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/cid\/ciw683","article-title":"RV254\/SEARCH 010, RV304\/SEARCH 013 and SEARCH 011 protocol teams. persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection","volume":"64","author":"Sereti","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib182","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.antiviral.2011.09.011","article-title":"Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection","volume":"92","author":"Shankaran","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib183","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/QAD.0b013e328330342c","article-title":"The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells","volume":"23","author":"Shehu-Xhilaga","year":"2009","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.antiviral.2019.03.008_bib233","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JVI.05720-11","article-title":"Secretion modification region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release","volume":"86","author":"Shelton","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib184","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1126\/science.2825351","article-title":"Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I","volume":"238","author":"Siekevitz","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.03.008_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005142","article-title":"The depsipeptide romidepsin reverses HIV-1 latency in vivo","volume":"11","author":"S\u00f8gaard","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003834","article-title":"An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients","volume":"9","author":"Spina","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib187","doi-asserted-by":"crossref","first-page":"IL2","DOI":"10.1055\/s-0035-1556099","article-title":"Ingenol 3,20 dibenzoate efficiently reactivates latent HIV","volume":"81","author":"Spivak","year":"2015","journal-title":"Planta Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib188","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01361-18","article-title":"Synthetic ingenols maximize protein kinase C-induced HIV-1 latency reversal","volume":"62","author":"Spivak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.03.008_bib189","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/00002030-200207260-00004","article-title":"Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)","volume":"16","author":"Stellbrink","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ebiom.2015.11.047","article-title":"Small molecule inhibitors of BAF; a promising family of compounds in HIV-1 latency reversal","volume":"3","author":"Stoszko","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.antiviral.2019.03.008_bib191","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jinf.2017.09.004","article-title":"Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs","volume":"75","author":"Tapia","year":"2017","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2019.03.008_bib192","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.1038\/s41598-017-09129-w","article-title":"A clue to unprecedented strategy to HIV eradication: \u201cLock-in and apoptosis","volume":"7","author":"Tateishi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib193","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virol.2009.04.019","article-title":"TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells","volume":"389","author":"Thibault","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib194","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11908-018-0626-9","article-title":"Are non-HIV malignancies increased in the HIV-infected population?","volume":"20","author":"Thrift","year":"2018","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jep.2017.09.038","article-title":"The Croton megalobotrys M\u00fcll Arg. traditional medicine in HIV\/AIDS management: documentation of patient use, in vitro activation of latent HIV-1 provirus, and isolation of active phorbol esters","volume":"211","author":"Tietjen","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib196","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1099\/jgv.0.000402","article-title":"Modulation of apoptosis and viral latency - an axis to be well understood for successful cure of human immunodeficiency virus","volume":"97","author":"Timilsina","year":"2016","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib197","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.142.2.702","article-title":"Signaling through T lymphocyte surface proteins, TCR\/CD3 and CD28, activates the HIV-1 long terminal repeat","volume":"142","author":"Tong-Starkesen","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib198","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.antiviral.2019.03.008_bib199","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/cid\/cix1121","article-title":"Atypical skeletal muscle profiles in human immunodeficiency virus-infected asymptomatic middle-aged adults","volume":"66","author":"Tran","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib200","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02166-16","article-title":"Toll-like receptor 7 agonist GS-9620 induces HIV expression and HIV-specific immunity in cells from HIV-infected individuals on suppressive antiretroviral therapy","volume":"91","author":"Tsai","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib201","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/j.1460-2075.1996.tb00449.x","article-title":"Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation","volume":"15","author":"Van Lint","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.03.008_bib202","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1002\/j.1460-2075.1993.tb05994.x","article-title":"Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation","volume":"12","author":"Verdin","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.03.008_bib203","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.03.008_bib204","article-title":"WEPDA0202: role of UHRF1 in transcriptional regulation and maintenance of HIV-1 latency","volume":"15","author":"Victoriano","year":"2012","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.antiviral.2019.03.008_bib205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0042-6822(92)90295-Z","article-title":"Activation of human immunodeficiency virus type 1 provirus in T-cells and macrophages is associated with induction of inducer-specific NF-kappa B binding proteins","volume":"187","author":"Vlach","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib206","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12977-014-0088-6","article-title":"Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein","volume":"11","author":"Wan","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2019.03.008_bib207","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/COH.0000000000000298","article-title":"Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population","volume":"11","author":"Wandeler","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib208","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.1021\/acs.joc.6b02312","article-title":"Sesterterpenoids isolated from the sponge phorbas sp. activate latent HIV-1 provirus expression","volume":"81","author":"Wang","year":"2016","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib209","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1038\/s41598-017-07157-0","article-title":"Reactivation of HIV-1 from latency by an ingenol derivative from Euphorbia kansui","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.03.008_bib210","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1089\/aid.2006.22.854","article-title":"HIV type 1 inhibition by protein kinase C modulatory compounds","volume":"22","author":"Warrilow","year":"2006","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2019.03.008_bib211","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004071","article-title":"Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing","volume":"10","author":"Wei","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2019.03.008_bib212","first-page":"47","article-title":"HDAC inhibitors in HIV. Immunol","volume":"90","author":"Wightman","year":"2012","journal-title":"Cell Biol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib213","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1097\/QAD.0000000000000067","article-title":"Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells","volume":"27","author":"Wightman","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib214","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.03.008_bib215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062074","article-title":"Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients","volume":"8","author":"Winckelmann","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib216","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/emboj.2010.340","article-title":"A condensed view of chromatin during T cell development","volume":"30","author":"Wood","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2019.03.008_bib217","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/jac\/dkr496","article-title":"Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation","volume":"67","author":"Xing","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.03.008_bib218","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1128\/JVI.02033-10","article-title":"Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation","volume":"85","author":"Xing","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib219","first-page":"3473","article-title":"Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation","volume":"119","author":"Yang","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.antiviral.2019.03.008_bib220","article-title":"Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus","author":"Yang","year":"2017","journal-title":"Microb. Infect."},{"key":"10.1016\/j.antiviral.2019.03.008_bib221","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1093\/nar\/gkp707","article-title":"Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid","volume":"37","author":"Yeung","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.03.008_bib222","first-page":"265","article-title":"Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines","volume":"26","author":"Ying","year":"2010","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib223","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048832","article-title":"Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB","volume":"7","author":"Ying","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.03.008_bib224","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9927","article-title":"HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing","volume":"10","author":"Yukl","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2019.03.008_bib225","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02110-17","article-title":"Class 1-selective histone deacetylase (HDAC) inhibitors enhance HIV latency reversal while preserving the activity of HDAC isoforms necessary for maximal HIV gene expression","volume":"92","author":"Zaikos","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.03.008_bib226","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1021\/acs.jafc.7b00418","article-title":"Resveratrol reactivates latent HIV through increasing histone acetylation and activating Heat shock factor 1","volume":"65","author":"Zeng","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.antiviral.2019.03.008_bib227","article-title":"The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.antiviral.2019.03.008_bib228","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.18632\/oncotarget.6783","article-title":"Triptolide induces protective autophagy through activation of the CaMKK\u03b2-AMPK signaling pathway in prostate cancer cells","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.antiviral.2019.03.008_bib229","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.celrep.2012.09.008","article-title":"Reactivation of latent HIV-1 by inhibition of BRD4","volume":"2","author":"Zhu","year":"2012","journal-title":"Cell Rep."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421830679X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421830679X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:18Z","timestamp":1759062558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421830679X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":227,"alternative-id":["S016635421830679X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV \u201cshock and kill\u201d therapy: In need of revision","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}